Drug Database
DT

DTwP-HB-Hib vaccine (Pentavac SD, SSI / Pentavac PFS, SSI)

✓ Approved

Serum Institute of India Pvt. Ltd. · Vaccine · Vaccine

What is DTwP-HB-Hib vaccine?

DTwP-HB-Hib vaccine is a vaccine developed by Serum Institute of India Pvt. Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesPentavac SD, SSI, Pentavac PFS, SSI
CompanySerum Institute of India Pvt. Ltd.
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Serum Institute of India Pvt. Ltd.

Therapeutic Indications

DTwP-HB-Hib vaccine is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedFrontiers in plant science2026-11-11

Genome-wide comparative analysis of homeobox transcription factors in rice and expression profiles of selected genes reveal potential tissue and developmental stage specificity as well as abiotic stress responsiveness.

Trejo-Téllez Libia Iris LI, Saavedra-Ávila José Ignacio JI, Escobar-Sepúlveda Hugo Fernando HF, Gómez-Merino Fernando Carlos FC

Homeobox (HB) transcription factors are essential for plant development and can participate in regulating plant responses to diverse biotic and abiotic stresses. In this study, we performed an in-silico analysis of the different HB gene and protein subfamilies in rice, including Oryza sativa subsp. indica and O. sativa subsp. japonica. A total of 112 and 156 sequences annotated as HB transcription factors were retrieved from PlantTFDB for O. sativa subsp. indica and subsp. japonica, respectively, which showed 94% sequence identity. The homeobox-plant homeodomain finger (HB-PHD) subfamily showed 100% identity, whereas the three-amino-acid-loop-extension (TALE), WUSCHEL-related homeobox (WOX), and zinc-finger-homeodomain (ZF-HD) subfamilies displayed values equal to or higher than 95%; in contrast, HB-OTHERS showed the lowest identity (82%). Phylogenetic analysis grouped the proteins into six major subfamilies: HB-PHD, HD-ZIP, TALE, WOX, ZF-HD, and HB-OTHERS. In the promoter regions of HB genes of O. sativa subsp. japonica, 688 cis-regulatory motifs were retrieved as potentially associated with hormonal and stress responses such as drought, salinity, and cold; among the most frequent were ABRE, CGTCA-motif, TGACG-motif, and ARE. In addition, de novo motif analysis retrieved regulatory patterns specific to HB genes with significant similarity to transcription factors reported in specialized databases, suggesting conserved regulatory mechanisms. Selected representative genes from the TALE, WOX, and HD-ZIP subfamilies displayed relatively high expression under salinity or drought conditions. Overall, our findings expand the understanding of the diversity and potential functions of HB transcription factors in rice, providing a comparative framework and a set of candidate HB genes for subsequent experimental studies addressing their roles in rice development and abiotic-stress responses.

PMID 43011344
Read full article →
PubMedMetabolic syndrome and related disorders2026-11-11

Association Between Hemoglobin Concentration and Metabolic Syndrome in a Japanese Population.

Moriyama Kengo K

Hemoglobin (Hb) concentration has been associated with metabolic abnormalities, but its relationship with metabolic syndrome (MetS) remains incompletely characterized. We examined these associations in a Japanese health checkup population. This cross-sectional study included 17,567 adults (10,175 men and 7392 women) examined between 2007 and 2024. MetS was defined according to the Japanese criteria. MetS analyses included 10,169 men and 7389 women after excluding nine participants with missing medication data. Sex-stratified regression, sensitivity, restricted cubic spline, and exploratory receiver operating characteristic analyses were performed. MetS was present in 1973 men (19.4%) and 310 women (4.2%). Higher Hb quartiles were generally accompanied by less favorable metabolic profiles. In adjusted linear models, Hb was positively associated with homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides, fasting plasma glucose, waist circumference, and body mass index in both sexes; the largest standardized association was with HOMA-IR (men, β = 0.264; women, β = 0.150). In the principal confounder-adjusted logistic model, the odds ratios for MetS per 1 g/dL higher Hb were 1.441 in men and 1.668 in women. Associations remained significant in all sensitivity analyses. Restricted cubic splines indicated significant nonlinearity in both sexes. The areas under the curve for Hb alone were 0.579 in men and 0.676 in women. Higher Hb levels were associated with prevalent MetS and adverse metabolic parameters in both sexes. Hb may provide ancillary metabolic information but is insufficient for standalone MetS screening. The cross-sectional design precludes causal inference.

PMID 43012347
Read full article →
PubMedNPJ vaccines2026-11-11

A structure-guided trivalent subunit vaccine confers maternal protection to neonatal piglets against PEDV and PDCoV.

Liu Jia J, Chen Longping L, Li Dan D, Wang Zhuo Z et al.

Antigenic divergence among porcine epidemic diarrhea virus (PEDV) genotypes and porcine deltacoronavirus (PDCoV) limits the cross-protection provided by current commercial vaccines. Here, employing a structure-guided antigen design strategy, we developed a trivalent subunit vaccine concurrently targeting PEDV G2a, PEDV G2b, and PDCoV. The vaccine antigen set comprises optimized spike ectodomain antigens, featuring stabilizing mutations, a heptad repeat 2 (HR2) deletion, a fused neutralizing epitope, and a flagellin adjuvant fused to the N-terminus. Formulated with MF59+CpG adjuvants, this trivalent vaccine elicited robust PEDV- and PDCoV-specific neutralizing antibody responses and Th1/Th2-associated cellular immune responses characterized by IFN-γ, IL-2, and IL-4 production in mice. Immunization of pregnant sows with 300 μg dose induced high-titer IgG, IgA, and colostral secretory IgA (SIgA) against all three target viruses. Although neutralizing antibody titers were comparable between the 100 μg and 300 μg dose groups, the 300 μg group showed higher and more persistent levels of colostral binding IgG and SIgA. Following maternal immunization, piglets that acquired maternal antibodies through colostrum exhibited reduced clinical diarrhea, lower fecal viral RNA shedding, and less severe intestinal lesions after challenge with PEDV G2a, PEDV G2b, or PDCoV. These findings support this structure-guided trivalent subunit vaccine as a promising candidate for maternal immunization against co-circulating porcine enteric coronaviruses.

PMID 43009510
Read full article →
PubMedHealth communication2026-11-11

Spiritual Health Locus of Control and COVID-19 Booster Intentions Among Hispanic Americans: A Culturally Grounded Extension of the Extended Parallel Process Model.

Kim Joon J, Jun Jungmi J, Zambrano Rodriguez Viviana Carolina VC

Declining uptake of COVID-19 boosters poses significant public health concerns. Hispanic Americans, who have experienced disproportionate pandemic impacts, report lower uptake of updated boosters than non-Hispanic White adults, partly attributable to vaccine hesitancy. Although religiosity plays a central role in Hispanic communities, little is known about how spiritually grounded beliefs shape cognitive and emotional responses to vaccination. This study integrates the extended parallel process model (EPPM) with spiritual health locus of control (SHLOC) to examine how exposure to faith-based and governmental vaccine information influences booster intention through spiritually grounded efficacy appraisals. Using an online survey of Hispanic American adults (N = 349), we tested a structural equation model linking SHLOC, perceived threat, efficacy beliefs, fear, and vaccination intentions. Results indicated that active SHLOC, reflecting beliefs in divine partnership in health, increased response efficacy and indirectly promoted booster intention and vaccine advocacy, whereas passive SHLOC, reflecting divine determinism, reduced self-efficacy and indirectly discouraged booster intention. Perceived threat was positively associated with fear, and efficacy beliefs emerged as the strongest predictors of booster intention. Mediation analyses supported serial pathways from message exposure to SHLOC to efficacy to intention, identifying spiritually grounded control beliefs as a culturally embedded mechanism in vaccine decision making. Findings suggest that faith-based engagement can function as either a protective or risk communication channel, depending on whether messages reinforce divine partnership or determinism. The study advances EPPM by identifying SHLOC as a culturally grounded antecedent to efficacy appraisal and offers implications for culturally responsive vaccine communication in Hispanic communities.

PMID 43012739
Read full article →
PubMedInternational journal for equity in health2026-11-11

Reaching zero-dose children through the Big Catch-Up initiative in the Eastern Mediterranean Region.

Elmahdy Eman E, Mere Osama O, Farrukh Saadia S, Alyousfi Mohamad Nihad MN et al.

Routine immunization (RI) is one of the most effective public health interventions for reducing childhood morbidity and mortality. However, recent disruptions to RI have created immunity gaps in the Eastern Mediterranean Region (EMR), increasing the number of zero-dose (ZD) and under-immunized children, particularly in countries affected by conflict, displacement, service disruption, and ongoing vaccine-preventable disease outbreaks. The Big Catch-Up (BCU) initiative aimed to identify and vaccinate missed children, close immunity gaps, and strengthen RI systems. In the six Gavi-supported EMR countries included in this study (Afghanistan, Pakistan, Somalia, Sudan, Syria, and Yemen), implementation targeted children aged 12-59 months. This study assessed progress in reaching ZD children during BCU implementation in these six countries. A descriptive, multi-country programmatic analysis was conducted using quantitative and qualitative data from BCU quarterly reports covering implementation from Q4 2024 to Q1 2026. Additional data sources included World health Organization (WHO and United Nations Children's Fund (UNICEF) Estimates of National Immunization Coverage (WUENIC), Gavi-approved vaccine dose data, and UNICEF vaccine shipment data. Quantitative analysis summarized administered doses, zero-dose targets, BCU coverage, vaccine consumption, and performance by country and antigen among children aged 12-59 months. Age-disaggregated analyses were conducted for children aged 12-23 months and 24-59 months. Qualitative information from country reports on implementation successes, challenges, and lessons learned was summarized by country and thematic area. During the BCU implementation period, 3.5 million zero-dose children were reached with Penta1 across the six countries, representing 53% of the estimated cumulative population of 6.6 million ZD children. Of the 57 million Gavi-approved vaccine doses, 98% were shipped to countries, and 47.7 million doses were administered, equivalent to 84% of approved doses. Implementation success was supported by targeted identification of areas with high numbers of zero-dose children, integrated outreach, integration with other health services, and recruitment of vaccinators and deployment of community health workers. Key challenges included insecurity, population movement, inaccessible districts, community refusal, and limited community engagement. Substantial progress in reaching missed children was reported during BCU implementation in high-priority EMR countries. Lessons learned highlight the importance of integrating catch-up vaccination with RI, strengthening microplanning, ensuring timely vaccine supply and financing, improving community engagement, and institutionalizing catch-up vaccination.

PMID 43009985
Read full article →
PubMedCancer medicine2026-11-11

Risk Stratification of Newly Diagnosed Multiple Myeloma: Predictive Value of First-Year Biomarker Trajectories Identified by Group-Based Trajectory Modeling.

Bai Hexiang H, Tang Wenjiao W, Li Yan Y, Xiang Bing B et al.

Multiple myeloma (MM) exhibits significant heterogeneity. Traditional risk stratification often relies on static baseline data, failing to capture the dynamic evolution of biomarkers. This study aimed to develop a prognostic model incorporating longitudinal biomarker trajectories to improve risk stratification for newly diagnosed MM patients. We retrospectively analyzed 635 patients from West China Hospital between February 1, 2017 and December 30, 2022. Biomarkers including M protein, free light chains (FLC), creatinine (Cr), hemoglobin (Hb), immunoglobulin levels, and others were collected monthly within the first-year post-treatment. Patients were randomly divided into an internal training (70%) and validation (30%) cohort. Group-based trajectory modeling (GBTM) and Kaplan-Meier analysis were used to identify distinct biomarker evolution patterns, and the GBTM risk model was validated by the lowest mean squared error (LMSE) method. Cox regression analysis and a nomogram were employed to develop a prognostic model to provide individualized survival probability estimates and were validated in the internal validation cohort using time-dependent ROC analysis. GBTM identified dFLC, IgM, Cr, and Hb trajectories as significant prognostic factors. Patients scoring ≥ 3 (high-risk) showed significantly poorer overall survival than those scoring < 3 (low-risk) in both the training (median OS 32.2 months vs. not reached, p < 0.0001) and validation cohorts (36.8 months vs. not reached, p < 0.005). Then we established a nomogram that included the GBTM risk group, ISS stage, age, frontline treatment, pulmonary disease, cardiovascular disease, and thrombotic events. The nomogram demonstrated good predictive performance with AUC values consistently above 0.7 for 2- and 3-year survival in both cohorts (Training: 0.71, 0.70; Validation: 0.70, 0.70). Our study successfully developed a prognostic risk stratification model for MM patients using biomarker trajectories. This model may help identify high-risk patients and predict long-term survival, offering a valuable tool for personalized treatment planning.

PMID 43010617
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about DTwP-HB-Hib vaccine